These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1293058)

  • 1. The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection.
    Di Rocco PH; Nacucchio MC; Sordelli DO; Mancuso F; Hooke AM
    Infection; 1992; 20(6):360-4. PubMed ID: 1293058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.
    Chandrasekar PH; Sluchak JA; Kruse JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1927-30. PubMed ID: 8239607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
    Omri A; Suntres ZE; Shek PN
    Biochem Pharmacol; 2002 Nov; 64(9):1407-13. PubMed ID: 12392822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
    Beaulac C; Sachetelli S; Lagacé J
    J Drug Target; 1999; 7(1):33-41. PubMed ID: 10614813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice.
    Fu KP; Hetzel N; Hung PP; Gregory FJ
    Chemotherapy; 1986; 32(2):166-72. PubMed ID: 3698725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of granulocyte colony-stimulating factor (G-CSF) in a granulocytopenic mouse model of Pseudomonas aeruginosa lung infection through enhanced phagocytosis and killing by alveolar macrophages through priming tumour necrosis factor-alpha (TNF-alpha) production.
    Shirai R; Kadota J; Tomono K; Ogawa K; Iida K; Kawakami K; Kohno S
    Clin Exp Immunol; 1997 Jul; 109(1):73-9. PubMed ID: 9218827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of antioxidant treatment in pneumonia of granulocytopenic rats].
    Xu JF; Qu JM; He LX; Zhang J; Li ZZ; Chen XH; Pan J; Li HP
    Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):853-6. PubMed ID: 15634548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose and schedule on cefoperazone pharmacodynamics in an in vitro model of infection in a neutropenic host.
    Zinner SH; Dudley MN; Gilbert D; Bassignani M
    Am J Med; 1988 Jul; 85(1A):56-8. PubMed ID: 3400681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model.
    Amura CR; Fontan PA; Sanjuan N; Sordelli DO
    Clin Immunol Immunopathol; 1994 Nov; 73(2):261-6. PubMed ID: 7923933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.
    Gerber AU; Craig WA; Brugger HP; Feller C; Vastola AP; Brandel J
    J Infect Dis; 1983 May; 147(5):910-7. PubMed ID: 6842025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice.
    Hoogeterp JJ; Mattie H; Terporten P
    Infection; 1988; 16(1):58-62. PubMed ID: 3129373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
    Cai Y; Yang D; Wang J; Wang R
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats.
    Marier JF; Brazier JL; Lavigne J; Ducharme MP
    J Antimicrob Chemother; 2003 Aug; 52(2):247-52. PubMed ID: 12837733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant protection against bacterial infection in granulocytopenic mice.
    Buhles WC; Shifrine M
    J Infect Dis; 1977 Jul; 136(1):90-5. PubMed ID: 328788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor alpha plus interleukin 1 beta treatment protects granulocytopenic mice from Pseudomonas aeruginosa lung infection: role of an unusual inflammatory response.
    Amura CR; Fontan PA; Sanjuan N; Nociari MM; Buzzola FR; Sordelli DO
    APMIS; 1995 Jun; 103(6):447-59. PubMed ID: 7546648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
    Alipour M; Suntres ZE
    Ther Deliv; 2014 Apr; 5(4):409-27. PubMed ID: 24856168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.
    Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
    Am J Med; 1988 Jul; 85(1A):21-30. PubMed ID: 3041815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
    Song Z; Wu H; Mygind P; Raventos D; Sonksen C; Kristensen HH; Høiby N
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3868-74. PubMed ID: 16127064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.
    Francis P; Lee JW; Hoffman A; Peter J; Francesconi A; Bacher J; Shelhamer J; Pizzo PA; Walsh TJ
    J Infect Dis; 1994 Feb; 169(2):356-68. PubMed ID: 8106769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic host defense peptide IDR-1002 reduces inflammation in Pseudomonas aeruginosa lung infection.
    Wuerth KC; Falsafi R; Hancock REW
    PLoS One; 2017; 12(11):e0187565. PubMed ID: 29107983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.